These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 12459649)

  • 1. Melanoma inhibitory activity: a novel serum marker for uveal melanoma.
    Schaller UC; Bosserhoff AK; Neubauer AS; Buettner R; Kampik A; Mueller AJ
    Melanoma Res; 2002 Dec; 12(6):593-9. PubMed ID: 12459649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteopontin and 'melanoma inhibitory activity': comparison of two serological tumor markers in metastatic uveal melanoma patients.
    Haritoglou I; Wolf A; Maier T; Haritoglou C; Hein R; Schaller UC
    Ophthalmologica; 2009; 223(4):239-43. PubMed ID: 19270465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receiver operating characteristic analysis: calculation for the marker 'melanoma inhibitory activity' in metastatic uveal melanoma patients.
    Klingenstein A; Haritoglou I; Schaumberger MM; Nentwich MM; Hein R; Schaller UC
    Melanoma Res; 2011 Aug; 21(4):352-6. PubMed ID: 21540751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
    Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R
    Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study.
    Reiniger IW; Wolf A; Welge-Lüssen U; Mueller AJ; Kampik A; Schaller UC
    Am J Ophthalmol; 2007 Apr; 143(4):705-7. PubMed ID: 17386288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
    Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
    Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Melanoma inhibitory activity" (MIA): a promising serological tumour marker in metastatic uveal melanoma.
    Reiniger IW; Schaller UC; Haritoglou C; Hein R; Bosserhoff AK; Kampik A; Mueller AJ
    Graefes Arch Clin Exp Ophthalmol; 2005 Nov; 243(11):1161-6. PubMed ID: 15906071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR.
    Mühlbauer M; Langenbach N; Stolz W; Hein R; Landthaler M; Buettner R; Bosserhoff AK
    Clin Cancer Res; 1999 May; 5(5):1099-105. PubMed ID: 10353744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma.
    Hofmann MA; Gussmann F; Fritsche A; Biesold S; Schicke B; Küchler I; Voit C; Trefzer U
    Melanoma Res; 2009 Feb; 19(1):17-23. PubMed ID: 19104451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MIA, a novel serum marker for progression of malignant melanoma.
    Bosserhoff AK; Lederer M; Kaufmann M; Hein R; Stolz W; Apfel R; Bogdahn U; Buettner R
    Anticancer Res; 1999; 19(4A):2691-3. PubMed ID: 10470221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Melanoma inhibitory activity (MIA). Evaluation of a new tumor-associated antigen as a serum marker for uveal melanomas].
    Schaller UC; Mueller AJ; Bosserhoff AK; Haraida S; Löhrs U; Buettner R; Kampik A
    Ophthalmologe; 2000 Jun; 97(6):429-32. PubMed ID: 10916387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dynamics of serum tumor markers in predicting metastatic uveal melanoma (part 1).
    Barak V; Kaiserman I; Frenkel S; Hendler K; Kalickman I; Pe'er J
    Anticancer Res; 2011 Jan; 31(1):345-9. PubMed ID: 21273622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MIA as a reliable tumor marker in the serum of patients with malignant melanoma.
    Stahlecker J; Gauger A; Bosserhoff A; Büttner R; Ring J; Hein R
    Anticancer Res; 2000; 20(6D):5041-4. PubMed ID: 11326664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated MIA serum levels are predictors of poor prognosis after surgical resection of metastatic malignant melanoma.
    Guba M; Steinbauer M; Ruhland V; Schütz A; Geissler EK; Anthuber M; Vogt T; Bosserhoff A; Jauch KW
    Oncol Rep; 2002; 9(5):981-4. PubMed ID: 12168059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of melanoma-inhibiting activity do not predict relapse in melanoma patients.
    Klimek VM; Williams L; Chapman PB
    Cytokines Cell Mol Ther; 2002 Dec; 7(2):71-4. PubMed ID: 12607797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using the direct-injection model of early uveal melanoma hepatic metastasis to identify TPS as a potentially useful serum biomarker.
    Barak V; Frenkel S; Valyi-Nagy K; Leach L; Apushkin MA; Lin AY; Kalickman I; Baumann NA; Pe'er J; Maniotis AJ; Folberg R
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4399-402. PubMed ID: 17898257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target.
    All-Ericsson C; Girnita L; Seregard S; Bartolazzi A; Jager MJ; Larsson O
    Invest Ophthalmol Vis Sci; 2002 Jan; 43(1):1-8. PubMed ID: 11773005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer.
    Aung PP; Oue N; Mitani Y; Nakayama H; Yoshida K; Noguchi T; Bosserhoff AK; Yasui W
    Oncogene; 2006 Apr; 25(17):2546-57. PubMed ID: 16331256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study.
    Kadkol SS; Lin AY; Barak V; Kalickman I; Leach L; Valyi-Nagy K; Majumdar D; Setty S; Maniotis AJ; Folberg R; Pe'er J
    Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):802-6. PubMed ID: 16505010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
    Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
    Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.